Is SkinPen FDA cleared, or is "approved" the right word?
SkinPen Precision is FDA cleared. It is not "approved" in the regulatory sense of that word, and the difference is not pedantic. The FDA authorized the original SkinPen through a De Novo request, DEN160029, with a decision date of March 1, 2018. That authorization created a new device classification, "powered microneedle device," under product code QAI and regulation 21 CFR 878.4430, as a Class II device. Approval, by contrast, is the term for Class III devices that pass premarket approval. For a clinic doing due diligence, those are three different routes with three different meanings.
The confusion is common because a lot of microneedling marketing uses "approved" loosely. When a vendor describes a pen as approved by the FDA, the accurate question to ask is which route the device actually went through and what record backs it. For SkinPen, that record is a De Novo number and a product code, both of which a buyer can look up. The rest of this article explains what each term means and why SkinPen's route was unusual.
Cleared, granted, approved: three different FDA routes
Most aesthetic devices reach the U.S. market through one of three paths. The terms are not interchangeable, and using the wrong one is a small but reliable signal that a description is marketing rather than regulatory fact.
| Route | FDA term | Device class | How it works |
|---|---|---|---|
| 510(k) | Cleared | Class II | Shown to be substantially equivalent to an existing legally marketed device (a predicate) |
| De Novo | Granted, then cleared | Class I or II | Used when no predicate exists; creates a new classification |
| PMA | Approved | Class III | Full premarket approval for higher-risk devices |
SkinPen sits in the middle row. Because no comparable microneedling device had been classified before it, a standard 510(k) was not available: there was nothing to be substantially equivalent to. The De Novo route exists for exactly that situation.
What a De Novo authorization is
A De Novo request asks the FDA to create a classification for a novel low-to-moderate-risk device that has no predicate. When the FDA grants it, two things happen at once: the specific device is authorized, and a new device category is established with its product code and regulation. Later devices of the same type can then use the ordinary 510(k) route, citing the De Novo device as their predicate. In other words, a De Novo grant turns one device into the founding member of a category.
For SkinPen, the De Novo (DEN160029) was decided on March 1, 2018. The classification it created is recorded by the FDA as "powered microneedle device," defined as a device that uses one or more needles to mechanically puncture and injure skin tissue for aesthetic use. That definition is a precise description of mechanical microneedling and, by design, excludes devices that add energy.
Product code and classification
The classification SkinPen created carries product code QAI under 21 CFR 878.4430, Class II. This is worth holding next to radiofrequency microneedling, which sits under a different regulation (21 CFR 878.4400) and product code GEI. The two categories are not the same paperwork, and a device's product code is one of the cleaner ways to tell mechanical microneedling from an energy-based system when reading FDA records rather than marketing copy. A clinic comparing options can use the code as a fast filter before reading anything else.
The practical takeaway: QAI and 878.4430 describe a needle-only device, which is consistent with how SkinPen works and inconsistent with any claim that it delivers radiofrequency or other energy. The device-level detail of the handpiece and consumable, including the single-use cartridge cleared as part of the protocol, is set out in the guide to the single-use cartridge cleared as part of the protocol, and the device overview lives in the SkinPen overview.
What SkinPen is cleared for
The De Novo also defines the specific use the FDA authorized, and the cleared indication is narrow. The SkinPen Precision System is, in the FDA wording, a microneedling device and accessories intended to improve the appearance of facial acne scars in adults aged 22 years or older. It is a prescription-use device, and the clinical study supporting it covered Fitzpatrick skin types II to VI. Broader uses that clinics associate with microneedling, such as texture or tone, fall outside that cleared wording and are a matter for the treating practitioner rather than the clearance.
Depth carries a related limit worth knowing at purchase. The device can be set up to 2.5 mm, but the FDA summary states that safety and effectiveness for settings greater than 1.5 mm have not been evaluated, and the labeling carries that precaution. The mechanical range and the clinically evaluated range are not the same number, which is the kind of detail that separates the FDA record from marketing copy.
"First FDA-cleared microneedling device": what the claim means
SkinPen is frequently described as the first FDA-cleared microneedling device. Against the FDA record, that claim holds up when stated precisely. Because the 2018 De Novo created the powered microneedle device classification, there was no earlier device of this type authorized in that category. SkinPen was the device that originated it. The careful wording is that SkinPen was the first microneedling device authorized in this classification, rather than a vague statement that everything else on the market is unregulated, which is not true: other devices have since been cleared, and some pens are sold for at-home or non-device use entirely.
De Novo as a category-creator, and why it is relevant for buyers
SkinPen is not the only aesthetic device to have created its own FDA category through a De Novo. Ultherapy, which was also authorized through a De Novo, established the micro-focused ultrasound category in 2009 in much the same way. The pattern is useful to recognize: a De Novo origin tells a buyer that the device defined its category rather than following one, which is a different regulatory history from a 510(k) device cleared against a predecessor.
For procurement, the lesson is simple. When a SkinPen device or its consumables are offered for sale, the verifiable facts are the De Novo number (DEN160029), the product code (QAI), and the device class (II). Pinova carries professionally sourced SkinPen cartridges, and the underlying clearance record is public, so a clinic can confirm the regulatory status of the system it is buying into rather than relying on a vendor's choice of words. Current consumables are listed under professionally sourced SkinPen cartridges.
Frequently asked questions
Is SkinPen approved by the FDA?
SkinPen is FDA cleared, not approved. Approval is the term for Class III devices that go through premarket approval. SkinPen is a Class II device authorized through the De Novo route in 2018.
What is a De Novo clearance?
A De Novo is the route the FDA uses for a novel low-to-moderate-risk device with no predicate. It authorizes the device and creates a new classification at the same time, so later similar devices can use a standard 510(k) citing it.
Is SkinPen really the first FDA-cleared microneedling device?
Stated precisely, yes. The 2018 De Novo (DEN160029) created the powered microneedle device classification, so SkinPen was the first microneedling device authorized in that category. It does not mean later devices are unregulated.
What product code and regulation cover SkinPen?
SkinPen falls under product code QAI and regulation 21 CFR 878.4430, as a Class II device. Radiofrequency microneedling sits under a different regulation, 21 CFR 878.4400, product code GEI.
